Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia

The study was approved by the appropriate institutional review boards. After complete description of the study to the subjects, written informed consent was obtained. Thirty clinically stable outpatients with schizophrenia diagnosed by DSM-IV criteria were enrolled. Inclusion criteria included a score of 27 or greater on the Scale for the Assessment of Negative Symptoms (SANS), treatment with a stable dose of clozapine for at least 4 weeks, and no other antipsychotic medications in oral form for at least 3 months or in depot form for 6 months. Patients with current major depressive episode or substance abuse were excluded.

The patients underwent a 2-week single-blind placebo lead-in followed by an 8-week randomly assigned double-blind treatment phase with 30 g of glycine in 7 ounces of lemonade twice a day or a similar-tasting and identical-appearing placebo mixture. Stable solutions of glycine were made biweekly from bulk powder. Clozapine was continued unchanged.

Measures used for biweekly assessments included the Brief Psychiatric Rating Scale (BPRS), SANS, Positive and Negative Syndrome Scale, Global Assessment Scale, and Simpson-Angus Rating Scale. The Hamilton Depression Rating Scale was administered at baseline. Tests for cognitive functioning performed at baseline and week 8 included the Stroop; WAIS vocabulary, information, digit span, and block design subtests; California Verbal Learning Test; finger tapping; and judgment of line orientation. Serum for amino acid measurement was sampled between 10:00 a.m. and 2:00 p.m. at baseline and week 8.

Two patients dropped out during the single-blind placebo phase, and one patient dropped out on day 4 of glycine treatment. One patient receiving glycine stopped all medications during week 5 and required hospitalization; this subject’s final assessment at week 4 was carried forward for statistical analysis. Although an adverse effect of glycine cannot be ruled out in this patient, ratings of psychosis and general psychopathology were lower at week 4 than baseline. No patient met the placebo response criterion (20% improvement in total SANS) during the placebo lead-in phase. Clinical staff observed medication administration in 10 of the 14 subjects randomly assigned to receive glycine.

We analyzed results from 27 patients. Six were women, and 21 were men; their mean age was 39 years (SD=7), mean duration of illness was 16 years (SD=7), mean clozapine dose was 455 mg/day (SD=116), mean baseline Hamilton depression scale score was 13 (SD=7), and mean Simpson-Angus Rating Scale score was 3 (SD=2). Fourteen patients received glycine, and 13 received placebo. There was no significant difference between the glycine and placebo groups in age, clozapine dose, or duration of illness. Change scores on all clinical measures, analyzed by using Student’s t test, showed no significant treatment effect (Table 1). Ninety-five percent confidence intervals for the change from baseline to week 8 for the glycine group and for the difference between the glycine and placebo groups included zero for all clinical and cognitive scales. Repeated measures analysis of variance revealed no significant treatment effect on any measure of positive or negative symptoms from baseline through week 8: SANS total (F=1.5, df=4, 24, p=0.21); Positive and Negative Syndrome Scale total (F=1.1, df=4, 24, p=0.35), positive subscale (F=0.7, df=4, 24, p=0.58), and negative subscale (F=0.4, df=4, 24, p=0.81); and BPRS (F=1.1, df=4, 22, p=0.38).

Mean serum glycine at baseline was 239 μmol/liter (SD=41); mean serum glycine at week 8 was 1390 μmol/liter (SD=1033). One patient had less than a three-fold increase in serum glycine. With that patient excluded, the mean increase in glycine levels was sixfold. Mean serum serine at baseline was 87 μmol/liter (SD=17); mean serine at week 8 was 274 μmol/liter (SD=195).

Consistent with the recent report by Potkin et al. (11), high-dose glycine did not improve negative symptoms when added to clozapine. However, we did not observe the relative worsening of positive symptoms detected by Potkin et al. Our finding of 4% improvement in SANS scores is in marked contrast to previous reports of 17%–30% improvement when a comparable dose of glycine was added in patients primarily treated with conventional agents (8, 9). Both d-cycloserine and glycine appear to produce different responses when added to conventional neuroleptics than they do when added to clozapine (1, 3, 4, 10).

This is a small study of relatively short duration with a possibility of type II error. A longer trial with more subjects may be required to observe change in negative symptoms. However, previous studies with glycine using smaller samples and lasting 6 and 8 weeks have demonstrated significant improvement in negative symptoms (8, 9). Also, this study was performed in an outpatient setting, where compliance could not be ensured and observations were limited to biweekly evaluations. However, most of the patients were living in residences with supervised medication administration, and glycine levels indicated they were compliant with the study drug.

These data, combined with data from previous trials with d-cycloserine and glycine, suggest that agonists at the glycine site may be less effective when combined with clozapine than with conventional antipsychotics. These data also add to a growing body of evidence suggesting that relative activity at the glycine site of the NMDA receptor may contribute to differences in clinical efficacy between conventional and novel antipsychotic medications.

Presented in part at the NIMH New Clinical Drug Evaluation Unit Meeting, Boca Raton, Fla., June 10–13, 1998. Received Aug. 16, 1999; revision received Nov. 9, 1999; accepted Nov. 10, 1999. From the Psychotic Disorders Unit of the Massachusetts General Hospital; the Consolidated Department of Psychiatry, Harvard Medical School; and the New England Medical Center, Tufts University Medical School, Boston. Address reprint requests to Dr. Evins, Freedom Trail Clinic, 25 Staniford St., Boston, MA 02114; [email protected] (e-mail). Supported by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (Dr. Evins).